FATORES DE CRESCIMENTO NA CICATRIZAÇÃO DE ÚLCERAS DIABÉTICAS
DOI:
https://doi.org/10.13037/rbcs.vol11n38.1996Palavras-chave:
Fator de crescimento epidermal, fator de crescimento fibroblástico, fator de crescimento derivado de plaquetas, fator de crescimento endotelial vascularResumo
Introdução: A neuropatia diabética é a complicação crônica mais prevalente do Diabetes mellitus, e é relacionada com elevado risco de úlceras e amputações, retardo da cicatrização e maior risco de infecções. O uso tópico dos fatores de crescimento (GF) pode representar importante elemento coadjuvante no tratamento de úlceras diabéticas por suas propriedades angiogênica e mitogênica. Objetivos: O objetivo deste trabalho foi realizar revisão bibliográfica de trabalhos experimentais e ensaios clínicos utilizando topicamente os fatores de crescimento derivado de plaquetas, insulínico, epidermal, fibroblático básico e endotelial vascular. Resultados e conlusões: Os resultados apresentados foram promissores na aceleração da cicatrização de úlceras diabéticas e na prevenção de amputações, principalmente quando os mesmos foram utilizados em associação, ou em veículos de tecnologia avançada, como géis tridimensionais de colágeno, hidrogéis ou colágeno hidrolizado, colágeno reticulado, esponja de colágeno gelatinosa, proteínas de fusão (vitronectina), micro esferas de gelatina, encapsulamento em nanopartículas e derme artificial.
Downloads
Referências
1. Magalhães CEV, Bosuskela E. Pé diabético e doença vascular: entre o conhecimento acadêmico e a realidade clínica. Arq Bras Endocrinol Metab. 2011; 52(7):1073-75.
2. Kolluru GK, Bir SC, Kevil CG. Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. Int J Vasc Med. 2011; 30:155-85.
3. Rodriguez DL, Castelao AM, Gorriz JL, Alvaro F, Gonzales JN. Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy. World J Diabetes. 2012; 153(1):7-18.
4. Kruger D. Neo-intimal hyperplasia, diabetes and endovascular injury. Cardiovasc J Afr. 2012; Oct; 23(9):507-11.
5. Hinchliffe RJ, Valk GD, Apelqvist DG, Arstrong K, Bakker FL, Game FL, Hartemann-Heurtier A, Löndahl M, Price PE, van Houtum WH, Jeffcoate WJ. A systematic review of the effectiveness of interventions to enhance the healing of chronic ulcers of the foot in diabetes. Diabetes Metab Res Rev. 2008 May-Jun; 24(1):119-44.
6. Siersma V, Thorsen H, Holstein PE, Kars M, Apelqvist J, Jude EB, Piaggesi A, Bakker K, Edmonds M, Jirkovska A, Mauricio D, Ragnarson Tennvall G, Reike H, Spraul M, Uccioli L, Urbancic V, van Acker K, van Baal J, Schaper NC. Importance of factors determining the low health-related quality of life in people presenting with a diabetic foot ulcer: the Eurodiale study. Diabet Med. 2013 Nov; 30(11):1382-7.
7. Moura LI, Dias AM, Carvalho E, de Sousa HC. Recent advances on the development of wound dressings for diabetic foot ulcer treatment-A review. Acta Biomater. 2013 Jul; 9(7):7093-114.
8. Lee KM, Kim WH, Lee JH, Choi MS. Risk factors of treatment failure in diabetic foot ulcer patients. Arch Plast Surg. 2013 Mar; 40(2):123-8.
9. Richmond NA, Maderal AD, Vivas AC. Evidence-based management of common chronic lower extremity ulcers.
Dermatol Ther. 2013 May-Jun; 26(3):187-96.
10. Galiano RD, Pelo CR, Bhatt KI, Callaghan M, Bastidas N, Bunting S, et al. Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells. Am J Pathol. 2004 Jun; 164(6):1935-47.
11. Dumville JC, Soares MO, Omeara S. Systematic review and mixed treatment comparison: dressings to heal diabetic foot ulcers. Diabetologia. 2012 Jul; 55(7):1902-10.
12. Andrae J, Gallini R, Betschultz C. Role of plateletderived growth factors in physiology and medicine. Genes Dev. 2008 May; 22(10):1276-312.
13. Wu OH, Chen WS, Chen OX, Wang JH, Zhang XM. Changes in the expression of platelet derived growth factor astrocytes in diabetic rats with spinal cord injury. Chin Med J (Engl). 2010 Jun; 123(12):1577-81.
14. Niezgoda N. Randomized clinical trial comparing Oasis wound matrix to Regranex gel for diabetic ulcers. Adv Skin Wound Care. 2005 Jun; 18(5 Pt 1):258-66.
15. Yang Y, Xia T, Zhi W, Wei L, Zhang C, Li X. Promotion of skin regeneration in diabetic rats by electrospun coresheath fibers loaded with basic fibroblast growth factor. Biomaterials. 2011 Jun; 32(18):4243-54.
16. Wieman TJ, Smiell JM, Su Y. Efficacy and safety of a topical gel formulation of recombinant human platelet-derived growth factor- B (becaplermin) in patients with chronic neuripathic diabetic ulcers. Diabetes Care. 1998 May; 21(5):822-7.
17. Landsman A, Agnew P, Freguesia L, Joseph R, Galiano RD. Diabetic foot ulcers treated with Becaplermin and Thera Gauze, a dressing intelligent humidity control: a randomized, multicenter, prospective analysis. J Am Podiat Med Assoc. 2010 May-Jun; 100(3):155-60.
18. Siddle K. Signalling by insulin and IGF receptors: supporting acts and new players. J Mol Endocrinol. 2011: 47(1):R1-R10
19. Ishii DN. Implication of insulin-like growth factors in the pathogenesis of diabetic neuropathy. Brain Res Rev. 1995 Jan; 20 (1):47-67.
20. Blakytny R, Jude EB, Martin-Gibson J, Boulton AJ, Ferguson MW. Lack of insulin like growth factor 1 (IGF1) in the basal keratinocyte layer of diabetic skin and diabetic foot ulcers. J Pathol. 2000 Apr; 190(5):589-94.
21. Pollak MN, Schernhammer ES, Hankinson SE. Insulinlike growth factor sand neoplasia. Nat Rev Cancer. 2004 Jul; 4(7):505-18.
22. Upton Z, Cuttle L, Noble A, Kempf M, Topping G, Malda J, Xie Y, Mill J, Harkin DG, Kravchuk O, Leavesley DI, Kimble RM. Vitronectin: growth factor complexes have potential as a therapeutic healing. J Invest Dermatol. 2008 Jun; 128(6):1535-44.
23. Dawson RA, Upton Z, Malda J, Harkin DG. Preparation of cultured skin for transplantation using insulin-like growth factor I in conjunction with insulin-like binding protein 5 growth factor, epidermal growth factor, and Vitronectin. Transplantation. 2006 Jun; 81(12):1668-76.
24. Hardwicke J, Schmalijohann D, Boyce D, Thomas D. Epidermal growth factor therapy and wound healing – past, present and future perspectives. Surgeon. 2008 Jun; 6(3):172-7.
25. Oxford GE, Tayari L, Barfoot MD, Peck AB, Tanaka Y, Humphrey BM. Salivary EGF levels reduced in diabetic patients. J Diabetes Complications. 2000 May-Jun; 14(3):140-5.
26. Amin AH, Abd Elmageed ZY, Nair D, Partyka IM, Kadowistz PJ, Belmadani S, Matrougui K. Modified multipotent stromal cells with epidermal growth factor restore vasculogenesis and blood flow in ischemic hind-limb of type li diabetic mice. Lab Invest. 2010 Jul; 90(7):985-96.
27. Kim HS, Yoo HS. In vitro and in vivo epidermal growth factor gene therapy for diabetic ulcers with electrospun fibrous meshes. Acta Biomater. 2013 Jul; 9(7):7371-80.
28. Tsang MW, Wong WK, Hung CS, Lai KM, Tang W, Cheung EY, Kam G, Leung L, Chan CW, Chu CM, Lam EK. Human epidermal growth factor enhances healing of diabetic foot ulcers. Diabetes Care. 2003 Jun; 26(6):1856-61.
29. Hong JP, Jung HD, Kim YW. Recombinant Human epidermal growth factor (EGF) to enhance healing of diabetic foot ulcers. Ann Plast Surg. 2006 Apr; 56(4):394-8.
30. Monhan VK. Recombinant human epidermal growth factor (REGEN-D 150): effect on the healing of diabetic foot ulcers. Diabetes Res Clin Pract. 2007 Dec; 78(3):405-11.
31. Valenzuela-Silva CM, Tuero-Iglesias AD, García-Iglesias E, González-Diáz O, Del Rio-Martín A, Alos IBY, FernándezMontequín JI, López-Saura PA. Granulation response and partial wound closure predict healing in clinical trials on advanced diabetes foot ulcers treated with recombinant human epidermal growth factor. Diabetes Care. 2013 Feb; 36:210-5.
32. Tuyet HL, Nguyen Quynh TT, Vo Hoang Minh H, Thi Bich DN, Do Dinh T, Le Tan D, Van HL, Le Huy T, Doan Huu H, Tran Trong TN. The efficacy and safety of epidermal growth factor in the treatment diabetic foot ulcers: the preliminary results. Int Wound J. 2009 Apr; 6(2):159-66.
33. Fernández-Montequín JI, Valenzuela-Silva CM, Díaz OG, Savigne W, Sancho-Soutelo N, Rivero-Fernández F, Sánchez-Penton P, Morejón-Vega L, Artaza-Sanz H, GarcíaHerrera A, González-Benavides C, Hernández-Cañete CM, Vázquez-Proenza A, Berlanga-Acosta J, López-Saura PA; Cuban Diabetic Foot Study Group. Intra-lesional injections of recombinant human epidermal growth factor promote
granulation and healing in advanced diabetic foot ulcers: a multicenter randomized, placebo-controlled, double-blind study. T Wound J. 2009 Dec; 6(6):432-43.
34. Choi JK, Jang JH, Jang WH, Kim J, Bae J, Bae IH, Park YH, Kim BJ, Lim KM, Park JW. The Effect of Epidermal Growth Factor (EGF), Coupled With Low Molecular Weight Protamine (LMWP) on Healing of Skin. Biomaterials. 2012 Nov; 33(33):8579-90.
35. Dogan S, Demirer S, Kepenekci I, Erkek B, Kiziltay A, Hasirci N, Müftüoglu S, Nazikoglu A, Renda N, Dincer UD, Elhan A, Kuterdem E. Epidermal growth factor-containing wound closure enhances wound healing in diabetic and non-diabetic mice. Int Wound J. 2009 Apr; 6(2):107-15.
36. Kondo S, Niiyama H, Kuroyanagi Y. Evaluation of a wound dressing composed of hyaluronic acid and collagen sponge containing epidermal growth factor in diabetic. J Biomater Sci Polym Ed. 2011 Sep; 128:756-92.
37. Chu Y, Yu D, Wang P, Xu J, Li D, Ding M. Nanotechnology promotes the total thickness diabetic wound healing effect of recombinant human epidermal growth factor in diabetic rats. Wound Repair Regen. 2010 Sep-Oct; 18(5):499-505.
38. Hardwicke JT, Hart J, Bell U, Duncan R, Thomas DW, Moseley R. The effect of dextrin-rh EGF on the healing of full thickness excisional wounds in (db / db) diabetic mouse.Control Release. 2011 Jun; 152(3):411-7.
39. Lao G, Yan L, Yang C, Zhang L, Zhang S, Zhou Y. Controlled release of epidermal growth factor from hydrogels accelerates wound healing in diabetic mice. J Am Podiatr Med Assoc. 2012 Mar-Apr; 102(2):89-98.
40. Itoh N. Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Re. 2010 Oct; 342(1):1-11.
41. Medeiros AC, Dantas AM, Aires NT, Lima FP, Azevedo IM, Alves SG. O fator de crescimento de fibroblasto básico melhora a cicatrização de anastomoses duodenais em ratos. Acta Cir Bras. 2003; 18(1):10-4.
42. Ono I. The effects of basic fibroblast growth factor (FGFb) on the breaking strength of acute incisional wounds. J Dermatol Sci. 2002 Aug; 29(2):104-13.
43. Dantas-Filho AM, Aguiar JL, Rocha LR, Azevedo IM, Ramalho E, Medeiros AC. Effects of the basic fibroblast growth factor and
its anti-factor in the healing and collagen maturation of infected skin wound. Acta Cir Bras. 2007 Mar-Apr; 22(Suppl 1):64-71.
44. Uchi H, Igarashi A, Urabe K, Koga T, Nakayama J, Kawamori R, Tamaki K, Hirakata H, Ohura T, Furue M. Clinical efficacy of basic fibroblast growth factor (FGFb) for diabetic ulcer. Eur J Dermatol. 2009 Sep-Oct; 19(5):461-468.
45. Kawai K, Suzuki S, Tabata Y, Nishimura Y. Accelerated wound healing through the incorporation of basic fibroblast growth factor impregnated gelatin microspheres into artificial dermis using a pressure-induced decubitus ulcer model in genetically diabetic mice. Br J Plast Surg. 2005 Dec; 58(8):1115-23.
46. Morimoto N, Yoshimura K, Niimi M, Ito T, Tada H, Teramukai S, Murayama T, Toyooka C, Takemoto S, Kawai K, Yokode M, Shimizu A, Suzuki S. An exploratory clinical trial for combination therapy with wound care and an array novel fibroblast growth factor in patients with chronic skin ulcers: a study protocol. Am J Transl Res. 2012; 4(1):52-9.
47. Xie L, Zhang M, Dong B, Guan M, Lu M, Huang Z, Gao H, Li X. Improved refractory wound healing with administration of acidic fibroblast growth factor in diabetic rats. Diabetes Res Clin Pract. 2011 Sep; 93(3):396-403.
48. Huang Z, Lu M, Zhu G, Gao H, Xie L, Zhang X, Ye C, Wang Y, Sun C, Li X. Accelerated diabetic - wound healing in healing with pegylated rh FGFa disabled Streptozotocin diabetic rats. Wound Repair Regen. 2011 Sep-Oct; 19(5):633-44.
49. Wang W, Lin S, Xiao Y, Huang Y, Tan Y, Cai L, Li X. Acceleration of diabetic wound healing with chitosancrosslinked collagen sponge containing recombinant human acidic fibroblast growth factor in healing-impaired Stz diabetic rats. Life Sciences. 2008 Jan; 82(3-4):190-204.
50. Yan X, Chen B, Lin Y, Li Y, Xiao Z, Hou X, Tan Q, Dai J. Acceleration of Diabetic Wound Healing by CollagenBinding Vascular Endothelial Growth Factor in Diabetic Rat Model. Diabetes Res Clin Pract. 2010 Oct; 90(1):66-72.
51. Bauer SM, Liu ZJ, Chen H, Goldstein L, Velazquez OC. Vascular endothelial growth factor-C that promotes vasculogenesis, angiogenises and constriction of the collagen in the collagen gels tridimencisionais. J Vasc Surg. 2005 Apr; 41(4):699-707.
52. Waltermberger J, Lange J, Kranz A. Vascular endothelial growth actor-a-induced chemotaxis of monocytes is attenuated in patients with diabetes mellitus a potential predictor for the Individual capacity to develop collaterals. Circulation. 2000; 102:185-190.
53. Ko J, Jun H, Chung H, Yoon C, Kim T, Kwon M, Lee S, Jung S, Kim M, Park JH. Comparison of EGF with VEGF non-viral diabetic mice. Diabetes Metab J. 2011; 35(3):226-35.
54. Pawson EJ, Duran-Jimenez B, Surosky R, Brooke HE, Spratt SK, Tomlinson DR, Gardiner NJ. Engineered zinc finger protein mediated VEGF-A activation restores deficient VEGF-A in sensory neuronsin experimental diabetes. Diabetes. 2010 Feb; 59(2):509-18.
55. Tan Q, Chen B, Yan X, Lin Y, Xiao Z, Hou X, Dai J. Promotion of wound healing diabetic by collagen scaffold with collagen binding vascular endothelial growth factor in a diabetic rat model. J Tissue Eng Regen Med. 2012 May; 2:1513-28.
56. Upton Z, Wallace HJ, Shooter GK, van Lonkhuyzen DR, Yeoh-Ellerton S, Rayment EA, Fleming JM, Broszczak D, Queen D, Sibbald RG, Leavesley DI, Stacey MC. Human pilot studies reveal the potential of a Vitronectin: complex growth factor for the treatment of chronic wounds. Int Wound J. 2011 Oct; 8(5):522-32.
57. Alckermann M, Wolloscheck T, Wellmann A, Li VW, Li WW, Konerding MA. Priming with a combination of proangiogenic growth factors improves wound healing in diabetes induced by Streptozotocin in rats. Eur Surg Rev. 2011; 47(2):81-9.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2014 Maria Cristina Travi-Carneiro, Maria Isabel Carneiro-Travi, Patricia Martins Bock
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Proposta de Política para Periódicos que oferecem Acesso Livre Adiado
Autores que publicam nesta revista concordam com os seguintes termos:
- Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho licenciado simultaneamente sob uma licença
https://creativecommons.org/licenses/by-nc-nd/4.0/, permitindo o compartilhamento do trabalho com reconhecimento da autoria do trabalho e publicação inicial nesta revista.
- Autores têm autorização para assumir contratos adicionais separadamente, para distribuição não-exclusiva da versão do trabalho publicada nesta revista (ex.: publicar em repositório institucional ou como capítulo de livro), com reconhecimento de autoria e publicação inicial nesta revista.
- Autores têm permissão e são estimulados a publicar e distribuir seu trabalho online (ex.: em repositórios institucionais ou na sua página pessoal) a qualquer ponto antes ou durante o processo editorial, já que isso pode gerar alterações produtivas, bem como aumentar o impacto e a citação do trabalho publicado (Veja O Efeito do Acesso Livre).
